Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-19-006218
Filing Date
2019-01-11
Accepted
2019-01-10 18:18:03
Documents
3
Group Members
BLACKSTONE CLARUS III L.L.C.BLACKSTONE GROUP L.P.BLACKSTONE GROUP MANAGEMENT L.L.C.BLACKSTONE HOLDINGS I/II GP INC.BLACKSTONE HOLDINGS II L.P.CLARUS VENTURES III GP, L.P.CLARUS VENTURES III, LLCDENNIS HENNERKURT WHEELERNICHOLAS GALAKATOSNICHOLAS SIMONROBE

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13D d675475dsc13da.htm SC 13D/A 253094
2 EX-99.1 d675475dex991.htm EX-99.1 21467
3 EX-99.2 d675475dex992.htm EX-99.2 7860
  Complete submission text file 0001193125-19-006218.txt   284447
Mailing Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142
Business Address 101 MAIN STREET SUITE 1210 CAMBRIDGE MA 02142 617-949-2200
Clarus Lifesciences III, L.P. (Filed by) CIK: 0001597143 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1214
Type: SC 13D/A

Mailing Address 1490 O'BRIEN DRIVE, SUITE A MENLO PARK CA 94025
Business Address 1490 O'BRIEN DRIVE, SUITE A MENLO PARK CA 94025 (650) 352-4150
Forty Seven, Inc. (Subject) CIK: 0001667633 (see all company filings)

EIN.: 474065674 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90560 | Film No.: 19521120
SIC: 2834 Pharmaceutical Preparations